Molecular formula:C221H366N72O67S
Molecular weight: 5134.7233
Patent period: —
Dositive specifications:2 mg BASE/VIAL
Injection :2 mg /once day
Oral tablets: —
Injection: —
Molecular formula:C221H366N72O67S
Molecular weight: 5134.7233
Patent period: —
Dositive specifications:2 mg BASE/VIAL
Injection :2 mg /once day
Oral tablets: —
Injection: —
EGRIFTA is a growth hormone releasing factor (GRF) analogindicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy:
__ EGRIFTA
ACTIONS | — |
---|---|
CAS NO. | 218949-48-5 |
FORMULA | C221H366N72O67S |
M. WT | 5134.7233 |
PURITY | — |
SYNONYMS | TesamorelinAcetate Tesamorelin(usan)USP/EP/BP D06655 Tesamorelin (usan) |
STORAGE | — |